New Haven drug maker Biohaven Pharmaceuticals is looking to raise around $200 million in a secondary public offering.
Biohaven said Monday that it plans to sell 2.69 million shares of common stock at $76 a share.
The biopharma said it has granted the underwriter a 30-day option to buy up to an additional 402,961 shares at the offering price, minus discounts and commissions.
The offering is expected to close on Wednesday.
Biohaven, which trades on the New York Stock Exchange under the symbol BHVN, makes the commercial migraine drug Nurtec ODT, which won Food and Drug Administration approval in February 2020.
It is also working on treatments for neurological and psychiatric diseases including Alzheimer’s, obsessive compulsive disorder and amyotrophic lateral sclerosis (ALS).
It recently expanded into Science Park after acquiring New Haven’s Kleo Pharmaceuticals and its potential treatments for multiple myeloma and COVID-19.
Goldman Sachs & Co. LLC is acting as book-running manager for the offering.
Contact Natalie Missakian at news@newhavenbiz.com
